drugset / Trial / NCT00656084
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL
Timeline
- Start
- 2004-12
- Primary completion
- 2007-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 900 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 10 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |